Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Qingre Bawei** is a marketed traditional Mongolian medicine oral formulation used in China for heat-clearing and detoxifying indications, including lung heat cough, hemoptysis in sputum, and liver-fire rib pain. It is a **multi-herb/multi-ingredient prescription pharmaceutical** typically formulated as a capsule containing sandalwood, gypsum, safflower, violet herb, dianthus, picrorhiza, ophiopogon, and artificial bezoar. Its pharmacology is based on traditional medicine principles rather than a single validated molecular target, and modern clinical literature includes use as adjunctive therapy, such as combination with budesonide in acute exacerbation of chronic obstructive pulmonary disease. The exact manufacturer can vary by marketed product; identified marketed capsule products include brands and generics produced by Mongolian medicine manufacturers in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingre Bawei.